Stephen Hoffman

Dr. Hoffman has been Chief Executive Officer of Aerpio Pharmaceuticals since December 2017. Prior to Aerpio, Dr. Hoffman was a Senior Advisor to PDL BioPharma, an investment firm that managed a portfolio of investments in the biotech, pharmaceutical and medical device industries. From 2007 he was a Managing Director at Skyline Ventures, a venture capital firm, and was general partner at TVM Capital from 2003 to 2007. Prior to TVM, he was President, Chief Executive Officer of Allos Therapeutics from 1994 to 2002, where he remained as Chairman until 2012. Dr. Hoffman graduated from the University of Colorado School of Medicine where he also completed a fellowship in clinical oncology and a residency in dermatology and holds a Ph.D. in chemistry from Northwestern University.